必应词典为您提供progression-free-interval的释义,网络释义: 无瘤间期;缓解期;
Overall SurvivalProgression-Free IntervalPathwayConditionalOverall Survival (OS) and Progression-Free Interval (PFI) as survival times have been collected in The Cancer Genome Atlas (TCGA). It is of biomedical interest to consider their dependence in pathway detection and survival prediction. We intend...
待解决 悬赏分:1 - 离问题结束还有 the progression-free survival interval, however, forms a potential time framer for the expansion of tumor -specific T cells by CTLA4-specific antibodies in the absence of tumor-induced immune suprression问题补充:匿名 2013-05-23 12:21:38 的无进展生存时间间...
athe progression-free survival interval, however, forms a potential time framer for the expansion of tumor -specific T cells by CTLA4-specific antibodies in the absence of tumor-induced immune suprression 无进步生存间隔时间,然而,形成一个潜在的时间策划者为肿瘤-具体t淋巴细胞扩展由CTLA4具体抗体在没有...
In particular this shows that not only there are good values R but that all values R in the interval are good, when weakening the constant C_m by a small factor only. In particular, one can choose R= \lfloor \mu n \rfloor . In another direction, as the above argument does not ...
Keywords: papillary thyroid carcinoma; autophagy; lncRNAs; progression-free interval; I-131 therapy 1 Introduction The incidence of thyroid cancers (TC), the most frequent endocrine tumors, has been increasing during the past decades [1,2], largely due to the progressively available and sensitive ...
关键词: oncology event count analysis progression-free survival informative censoring interval censoring DOI: 10.1002/pst.251 被引量: 67 年份: 2007 收藏 引用 批量引用 报错 分享 全部来源 求助全文 Wiley 相似文献 参考文献 引证文献Analysis of progression-free survival in oncology trials: some common ...
The median progression-free survival was 16.5 months with osimertinib compared to 11.0 months for the standardtherapy, with a hazard ratio of 0.54 (95% confidence interval, 0.41-0.72; p<0.0001). The median duration of response was two-fold higher for patients treated with osimertinib (17.6 month...
The progression-free survival (PFS) of patients with NLR-low at baseline (n=26; median, not reached) was significantly better than that of patients with NLR-high (n=27; median, 4.13 months; hazard ratio [HR], 0.226; 95% confidence interval [CI], 0.112鈥 0.493; p=0.0001). Longer ...
The obtained linear regression equation was ΔOS =-0.088 (95% confidence interval [CI] -1.347-1.172) + 1.753 (95% CI 1.307-2.198) ×ΔPFS (R2=0.86). Conclusion: Results of this study indicate a significant association between PFS/TTP and OS in mBC, which may justify the use of PFS/...